<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT01065532</url>
  </required_header>
  <id_info>
    <org_study_id>EudraCT 2009-011440-20</org_study_id>
    <nct_id>NCT01065532</nct_id>
  </id_info>
  <brief_title>SEDUCE OCT Study in Coronary Artery rEstenosis:an Optical Coherence Tomography (OCT) Study</brief_title>
  <acronym>SEDUCE</acronym>
  <official_title>Healing Responses After Treatment of Bare Metal Stent Restenosis With Implantation of an Everolimus-eluting Xience V Stent Versus Use of a Paclitaxel-eluting Balloon: Optical Coherence Tomography Study</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>University Hospital, Gasthuisberg</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>University Hospital, Gasthuisberg</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      Different healing responses after treatment of bare metal stent restenosis with implantation
      of an everolimus-eluting Xience V stent (Abbott Vascular) versus use of a paclitaxel-eluting
      SeQuent Please balloon (BBraun): an optical coherence tomography study.

      A prospective, single-centre, randomized clinical trial with clinical, angiographic and OCT
      follow-up at 9 months.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Background: The optimal treatment of bare metal stent restenosis (implantation of a
      drug-eluting stent, simple balloon dilatation, CABG) is still not defined. The most used
      option nowadays is the implantation of a drug-eluting stent (DES). However, this procedure
      implies application of a double metal layer in the vessel wall, which is linked to delayed
      healing. Furthermore there might be a higher risk of malapposition of both struts of the bare
      metal and the newly implanted drug-eluting stents. These phenomenon's might give rise to an
      increased risk of stent thrombosis in this patient population. Recently, drug-eluting
      balloons (DEB) were proposed as a new treatment strategy for bare metal stent restenosis. The
      initial results of this technique look promising.

      Aim: To compare healing processes after treatment of BMS ISR with balloon dilatation using
      DEB versus implantation of DES.

      Methods: 50 patients with BMS restenosis (SVG and bifurcation lesions will be excluded) will
      be randomized into two treatment groups: SeQuent Please drug-eluting balloon dilatation
      (group I) versus implantation of an everolimus-eluting Xience V stent (group II). At 9
      months, a control angiography with OCT pullback of the treated segment is planned.
    </textblock>
  </detailed_description>
  <overall_status>Unknown status</overall_status>
  <last_known_status>Recruiting</last_known_status>
  <start_date>May 2009</start_date>
  <completion_date type="Anticipated">December 2015</completion_date>
  <primary_completion_date type="Anticipated">December 2010</primary_completion_date>
  <phase>N/A</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Stent strut coverage and stent strut apposition(assessed with OCT)</measure>
    <time_frame>9 months</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>Lumen Loss (in-stent) at 9 months In-segment Late Lumen Loss at 9 months Cumulative MACE rate at 9 months Stent thrombosis at all follow-ups Target vessel revascularisation (TVR) at 12 months Device success</measure>
    <time_frame>9 months, 12 months, yearly until 5 years</time_frame>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Anticipated">50</enrollment>
  <condition>Restenosis</condition>
  <arm_group>
    <arm_group_label>1</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>SeQuent Please Drug-eluting balloon</description>
  </arm_group>
  <arm_group>
    <arm_group_label>2</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Xience V Drug-eluting stent</description>
  </arm_group>
  <intervention>
    <intervention_type>Device</intervention_type>
    <intervention_name>Sequent Please Paclitaxel eluting balloon</intervention_name>
    <description>Sequent Please Paclitaxel eluting balloon</description>
    <arm_group_label>1</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Device</intervention_type>
    <intervention_name>Xience V everolimus eluting stent</intervention_name>
    <description>Xience V everolimus eluting stent</description>
    <arm_group_label>2</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          1. Patient older than 18 years

          2. written informed consent available

          3. patient eligible for percutaneous coronary intervention

          4. patients with a single or multiple re-stenotic lesion(s) in a previously stented area
             of a coronary artery (irrelevant whether BMS or DES)

          5. Target reference vessel diameter measured by QCA: 2-4 mm

          6. Target lesion length measured by QCA &lt; 24 mm

          7. Target lesion stenosis measured by QCA: &gt; 70%- &lt; 100%

          8. Patients willing to provide written informed consent prior to participation and
             willing and able to participate in all follow-up evaluations.

        Exclusion Criteria:

          1. Left ventricular ejection fraction of &lt; 30%

          2. Impaired renal function (serum creatinine &gt; 2.0 mg/dl)

          3. Target lesion located in bifurcation

          4. Previous and/or planned brachytherapy of target vessel

          5. Lesion of the left main trunk &gt; 50%, unprotected

          6. Known allergies to antiplatelet, anticoagulation therapy, contrast media, paclitaxel
             or everolimus

          7. Pregnant and/or breast-feeding females or females who intend to become pregnant
             (pregnancy test required)

          8. Patients with a life expectancy of less than one year

          9. Patients who intend to have a major surgical intervention within 6 months of enrolment
             in the study.

         10. Patient currently enrolled in other investigational device or drug trial

         11. Patient not able or willing to adhere to follow-up visits

         12. Patients who previously participated in this study. -
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Tom Adriaenssens, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>UZ Leuven</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Walter Desmet, MD, PhD</last_name>
    <role>Study Director</role>
    <affiliation>UZ Leuven</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Tom Adriaenssens, MD</last_name>
    <phone>+32 16 34 24 65</phone>
    <email>tom.adriaenssens@uzleuven.be</email>
  </overall_contact>
  <overall_contact_backup>
    <last_name>Walter Desmet, MD, PhD</last_name>
    <phone>+32 16 34 24 65</phone>
    <email>walter.desmet@uzleuven.be</email>
  </overall_contact_backup>
  <location>
    <facility>
      <name>University Hospitals Leuven</name>
      <address>
        <city>Leuven</city>
        <zip>3000</zip>
        <country>Belgium</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Tom Adriaenssens, MD</last_name>
      <phone>+32 16 34 24 65</phone>
      <email>tom.adriaenssens@uzleuven.be</email>
    </contact>
    <contact_backup>
      <last_name>Walter Desmet, MD, PhD</last_name>
      <phone>+32 16 34 24 65</phone>
      <email>walter.desmet@uzleuven.be</email>
    </contact_backup>
    <investigator>
      <last_name>Tom Adriaenssens, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
    <investigator>
      <last_name>Walter Desmet, MD, PhD</last_name>
      <role>Sub-Investigator</role>
    </investigator>
    <investigator>
      <last_name>Christophe Dubois, MD</last_name>
      <role>Sub-Investigator</role>
    </investigator>
  </location>
  <location_countries>
    <country>Belgium</country>
  </location_countries>
  <verification_date>April 2009</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>February 8, 2010</study_first_submitted>
  <study_first_submitted_qc>February 8, 2010</study_first_submitted_qc>
  <study_first_posted type="Estimate">February 9, 2010</study_first_posted>
  <last_update_submitted>February 9, 2010</last_update_submitted>
  <last_update_submitted_qc>February 9, 2010</last_update_submitted_qc>
  <last_update_posted type="Estimate">February 10, 2010</last_update_posted>
  <responsible_party>
    <name_title>Cardiology deparment University Hospitals Leuven Belgium</name_title>
    <organization>Cardiology deparment University Hospitals Leuven Belgium</organization>
  </responsible_party>
  <keyword>Restenosis</keyword>
  <keyword>PCI</keyword>
  <keyword>Drug-eluting stent</keyword>
  <keyword>Drug-eluting balloon</keyword>
  <keyword>Optical Coherence Tomography</keyword>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Paclitaxel</mesh_term>
    <mesh_term>Albumin-Bound Paclitaxel</mesh_term>
    <mesh_term>Everolimus</mesh_term>
    <mesh_term>Sirolimus</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

